Delineating endogenous Cushing's syndrome by GC-MS urinary steroid metabotyping.

Authors:
Braun LT; Osswald A; Zopp S; Rubinstein G; Vogel F and 15 more

Journal:
EBioMedicine

Publication Year: 2023

DOI:
10.1016/j.ebiom.2023.104907

PMCID:
PMC10776922

PMID:
38128413

Journal Information

Full Title: EBioMedicine

Abbreviation: EBioMedicine

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Genetics, Medical

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
5/6
83.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"table 2 (raw data"

Code Sharing
Evidence found in paper:

"Declaration of interests Several authors received funding as mentioned below. FB has received travel support by Novo Nordisk. Furthermore, he has a patent (PCT/EP2022/053142) for biomarkers for the diagnosis and treatment of endocrine hypertension, and methods of identification thereof. He also participated on an advisory board for Bayer (indication outside of the topic of the manuscript). All the other authors have no conflict of interest to report."

Evidence found in paper:

"This work is part of the German Cushing’s Registry CUSTODES and has been supported by a grant from the 10.13039/501100003042Else Kröner-Fresenius-Stiftung to M.R. (2012_A103 and 2015_A228). A.R., A.O., G.E., F.B., N.R. and M.R. are supported by the 10.13039/501100001659Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Projektnummer: 314061271-TRR 205) and N.R. also by 10.13039/501100001659DFG 325768017 and F.B. by the Clinical Research Priority Program of the 10.13039/501100006447University of Zurich for the CRPP HYRENE. L.T.B. and H.F.N. are supported by the Clinician Scientist program RISE, founded by the 10.13039/501100003042Else Kröner-Fresenius-Stiftung and the Eva-Luise-und-Horst-Köhler-Stiftung (2019_KollegSE.03). The funding sources had no involvement in this study."

Evidence found in paper:

"This work is part of the German Cushing’s Registry CUSTODES and has been supported by a grant from the 10.13039/501100003042Else Kröner-Fresenius-Stiftung to M.R. (2012_A103 and 2015_A228). A.R., A.O., G.E., F.B., N.R. and M.R. are supported by the 10.13039/501100001659Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Projektnummer: 314061271-TRR 205) and N.R. also by 10.13039/501100001659DFG 325768017 and F.B. by the Clinical Research Priority Program of the 10.13039/501100006447University of Zurich for the CRPP HYRENE. L.T.B. and H.F.N. are supported by the Clinician Scientist program RISE, founded by the 10.13039/501100003042Else Kröner-Fresenius-Stiftung and the Eva-Luise-und-Horst-Köhler-Stiftung (2019_KollegSE.03). The funding sources had no involvement in this study."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025